Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market, a market which is expected to grow, driven by the aging population and increasing prevalence of obesity. Yet a truly novel therapy has not been made available for this indication in nearly two decades. A successful launch in this population requires a deep understanding of current treatment patterns in this highly generic and OTC market. Over the past few years, branded therapies have launched in the OA pain market providing incremental safety, tolerability, and dosing benefits to overcome the drawbacks of the current standard of care nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics—but how have these agents fared in this highly generic market?
What patient share do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed OA pain patients?
How have novel branded agents such as abuse-deterrent opioids been integrated into the treatment algorithm? What level of uptake have older branded agents enjoyed and what were patients treated with prior to their switch to these agents?
What proportion of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of OA pain patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with OA pain?
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.